Top Markets
#1 ADO Protocol ADO Protocol +329.47%
#2 GoPlus Security GoPlus Security +54.27%
#3 Nockchain Nockchain +46.24%
#4 Tutorial Tutorial +35.05%
#5 Starpower Starpower +34.11%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +31.96%
#7 The Black Bull The Black Bull +31.29%
#8 GAIB AID GAIB AID +24.67%
#9 Casper Network Casper Network +21.33%
#10 Verus Coin Verus Coin +20.40%
Coin of the day
ADO Protocol ADO Protocol
Innstillinger
Språk
NORSK
Valuta
USD
Tema
China Regenerative Medicine International Limited China Regenerative Medicine International Limited

China Regenerative Medicine International Limited

8158
Rangering i aksjer #32812
China Regenerative Medicine International Limited operates as an investment... China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health management solutions, covering health condition assessments, detoxification programs, fostering internal bodily balance, nourishing vital organs, and enhancing the immune system. Additionally, its beauty offerings encompass non-surgical medical aesthetics, essential dermatological care, anti-aging skin remedies, hair revitalization, skin firming treatments, localized body contouring, and intimate restoration services. Established in 1995, the organization was previously known as China Bio-Med Regeneration Technology Limited until its rebranding to China Regenerative Medicine International Limited in March 2015. Its headquarters are situated in Tsim Sha Tsui, Hong Kong.
Aksjekurs
$0.02967889
Sist synkronisert: 2026-08-12
Markedsverdi
$9.03M
Endring (1 dag)
0.00%
Endring (1 år)
-72.68%
Land
HK
Handel China Regenerative Medicine International Limited (8158)

Kategori

Healthcare
P/E-forhold for China Regenerative Medicine International Limited (8158)
P/E-forhold per 2026 TTM: 0
Ifølge China Regenerative Medicine International Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for China Regenerative Medicine International Limited fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.